Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioNxt Solutions Inc. (BNXTF : OTC)

• Company Description    BioNxt Solutions Inc. is a bioscience accelerator focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations. BioNxt Solutions Inc., formerly known as XPhyto Therapeutics Corp., is based in VANCOUVER, BC. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.52 Daily Weekly Monthly 20 Day Moving Average: 21,624 shares Shares Outstanding: 115.76 (millions) Market Capitalization: $60.43 (millions) Beta: 0.80 52 Week High: $0.80 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.02% -21.14% 12 Week -30.05% -32.95% Year To Date 107.22% 81.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1820 Fir Street Suite 270 - Vancouver,BC V6J 3B1 CAN ph: 780-818-6422 fax: - None https://bionxt.com

• General Corporate Information    Officers Hugh Rogers - Chief Executive Officer Wolfgang Probst - Chief Financial Officer Raimar Lobenberg - Director Wolfgang Wagner - Director Oleksandr Zabutkin - Director Peer Information BioNxt Solutions Inc. (GSAC) BioNxt Solutions Inc. (CASI) BioNxt Solutions Inc. (ALCD.) BioNxt Solutions Inc. (OMNN) BioNxt Solutions Inc. (CGPI.) BioNxt Solutions Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 090974106 SIC: - Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 12/05/25 Share - Related Items Shares Outstanding: 115.76 Most Recent Split Date: (:1) Beta: 0.80 Market Capitalization: $60.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3,021.39 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -78.57% vs. Previous Quarter: -76.92% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -815.86 03/31/25 - -663.55 Current Ratio 09/30/25 - - 06/30/25 - 0.06 03/31/25 - 0.15 Quick Ratio 09/30/25 - - 06/30/25 - 0.06 03/31/25 - 0.15 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -27,362.50 03/31/25 - -24,411.76 Book Value 09/30/25 - - 06/30/25 - -0.05 03/31/25 - -0.05 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©